clonal evolution of aml on novel fms-like tyrosine kinase-3 (flt3) inhibitor therapy with evolving actionable targets
Clicks: 239
ID: 144979
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
239 views
69 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #11 of 15 articles by views in urology annals
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈https://clinicaltrials.gov/ct2/show/NCT02014558〉)
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (100 words).
Try re-searching for a better abstract.
| Reference Key |
kasi2016leukemiaclonal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Pashtoon M. Kasi;Mark R. Litzow;Mrinal M. Patnaik;Shahrukh K. Hashmi;Naseema Gangat |
| Journal | urology annals |
| Year | 2016 |
| DOI |
10.1016/j.lrr.2016.01.002
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.